Mapping opportunities for China's early cancer detection boom

Following the "small-scale" launch of its multicancer blood test in 2018, Mao said SeekIn has processed around 1,000 real-world samples, and receives about ten new samples per week. The company's SeekInCare test measures cfDNA copy number alterations and fragmentation profiles, plus a panel of seven proteins.

https://www.biocentury.com/article/630637/mapping-opportunities-for-china-s-early-cancer-detection-boom